Intuitive Surgical (NASDAQ:ISRG) stock is on the move Thursday after the company’s shares were given a price target increase by Barclays analysts.
Barclays analyst Matt Miksic increased the firm’s price target for ISRG stock from $430 per share to $490. That’s a potential upside of 15% over its prior closing price. It’s also above the analyst consensus price prediction of $426.53 per share.
The Barclays analyst reiterated the firm’s “overweight” rating for ISRG stock alongside that price target increase. For comparison, the analyst consensus rating for Intuitive Surgical shares is a moderate buy based on 19 opinions.
More Analyst Coverage of ISRG Stock
J.P. Morgan analysts also recently weighed in on Intuitive Surgical. Here’s what they said in a statement collected by MedTechDive:
“We think, if anything, the environment has improved modestly in China barring competitive headwinds, and while bariatric surgery should continue to remain pressured, given the low to mid-single digit % of procedures, we aren’t overly concerned.”
ISRG stock is down 2.5% as of Thursday afternoon. This comes with some 1.7 million shares traded, as compared to its daily average of about 1.3 million shares.
Investors will want to stick around for more of the most recent stock market stories today!
We have all of the hottest stock market news investors will want to read about on Thursday! A few examples include what’s happening with shares of Oklo (NYSE:OKLO), Warner Bros. Discovery (NASDAQ:WBD) and NKGen Biotech (NASDAQ:NKGN) stock today. All of this info is ready at the links below!
More Stock Market News for Thursday
- Cathie Wood Is Betting Big on Nuclear Energy Via Oklo Stock. What to Watch.
- WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
- Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
